Analysts Set IDEXX Laboratories, Inc. (NASDAQ:IDXX) Price Target at $783.33

IDEXX Laboratories, Inc. (NASDAQ:IDXX) has been assigned a consensus rating of “Moderate Buy” from the ten ratings firms that are presently covering the company, Marketbeat.com reports. Three equities research analysts have rated the stock with a hold rating and seven have assigned a buy rating to the company. The average 12 month price target among analysts that have covered the stock in the last year is $783.3333.

A number of analysts recently issued reports on IDXX shares. Leerink Partners set a $785.00 price target on shares of IDEXX Laboratories in a research note on Monday, November 3rd. Stifel Nicolaus set a $775.00 price objective on shares of IDEXX Laboratories in a report on Monday, November 3rd. Morgan Stanley upped their target price on shares of IDEXX Laboratories from $765.00 to $805.00 and gave the company an “overweight” rating in a research note on Tuesday, November 4th. BTIG Research reduced their price target on shares of IDEXX Laboratories from $830.00 to $800.00 and set a “buy” rating on the stock in a research report on Tuesday, February 3rd. Finally, Barclays lowered their price objective on IDEXX Laboratories from $850.00 to $800.00 and set an “overweight” rating for the company in a report on Thursday, February 5th.

IDEXX Laboratories Stock Performance

NASDAQ:IDXX opened at $649.35 on Friday. The firm has a 50-day moving average of $675.31 and a two-hundred day moving average of $669.07. The company has a debt-to-equity ratio of 0.23, a current ratio of 1.23 and a quick ratio of 0.90. The stock has a market cap of $51.70 billion, a P/E ratio of 49.68, a PEG ratio of 3.79 and a beta of 1.67. IDEXX Laboratories has a 1-year low of $356.14 and a 1-year high of $769.98.

IDEXX Laboratories (NASDAQ:IDXX) last issued its quarterly earnings results on Monday, February 2nd. The company reported $2.92 EPS for the quarter, missing analysts’ consensus estimates of $2.93 by ($0.01). IDEXX Laboratories had a net margin of 24.62% and a return on equity of 69.78%. The business had revenue of $1.09 billion during the quarter, compared to analysts’ expectations of $1.07 billion. During the same period in the prior year, the company posted $2.53 EPS. The company’s revenue for the quarter was up 14.3% on a year-over-year basis. IDEXX Laboratories has set its FY 2026 guidance at 14.290-14.800 EPS. On average, research analysts expect that IDEXX Laboratories will post 11.93 earnings per share for the current fiscal year.

Insider Activity at IDEXX Laboratories

In related news, EVP Michael G. Erickson sold 5,371 shares of the company’s stock in a transaction that occurred on Tuesday, February 17th. The stock was sold at an average price of $627.38, for a total transaction of $3,369,657.98. Following the sale, the executive vice president directly owned 12,693 shares of the company’s stock, valued at approximately $7,963,334.34. This represents a 29.73% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, Director Sophie V. Vandebroek sold 1,464 shares of IDEXX Laboratories stock in a transaction on Tuesday, February 17th. The stock was sold at an average price of $628.62, for a total transaction of $920,299.68. Following the completion of the transaction, the director directly owned 648 shares of the company’s stock, valued at approximately $407,345.76. This represents a 69.32% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. In the last ninety days, insiders have sold 18,180 shares of company stock valued at $11,626,996. Corporate insiders own 0.98% of the company’s stock.

Institutional Investors Weigh In On IDEXX Laboratories

Several institutional investors and hedge funds have recently bought and sold shares of the business. Virtus Advisers LLC acquired a new position in IDEXX Laboratories during the 3rd quarter worth $26,000. Park Place Capital Corp acquired a new stake in IDEXX Laboratories in the fourth quarter worth about $29,000. WealthCollab LLC acquired a new stake in IDEXX Laboratories in the second quarter worth about $30,000. J.Safra Asset Management Corp bought a new position in IDEXX Laboratories in the 3rd quarter valued at about $31,000. Finally, Armstrong Advisory Group Inc. increased its stake in IDEXX Laboratories by 55.9% during the 3rd quarter. Armstrong Advisory Group Inc. now owns 53 shares of the company’s stock valued at $34,000 after buying an additional 19 shares during the period. Institutional investors and hedge funds own 87.84% of the company’s stock.

IDEXX Laboratories Company Profile

IDEXX Laboratories, Inc (NASDAQ: IDXX) is a global developer, manufacturer and provider of diagnostic products and services primarily for the animal health, water testing and food safety markets. Headquartered in Westbrook, Maine, the company supplies in-clinic diagnostic instruments, consumables, reference laboratory testing and practice-management tools that support veterinarians, livestock and dairy producers, and utilities and food producers worldwide.

IDEXX’s product portfolio includes point-of-care tests and immunoassays designed for rapid diagnosis in veterinary clinics, in-clinic chemistry and hematology analyzers, automated urinalysis systems, and digital diagnostic solutions.